This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Results of the first multicenter clinical trial of recombinant human tissue-type plasminogen activator have taken the thrombolytic protein "out of the speculative pilot phase and put it into the clinically useful phase."
That is the assessment of Burton E. Sobel, MD, director of cardiology at Washington University School of Medicine-Barnes Hospital Medical Center, St Louis, one of the three trial locations (JAMA [MEDICAL NEWS] 1984;251:1651-1652).
Speaking at the annual meeting of the American Heart Association in Miami Beach, Sobel said he considers the successful trial—in which intravenously injected recombinant human tissue-type plasminogen activator opened coronary arteries in 35 of 50 patients with transmural infarctions and angiographically documented coronary occlusions—"a reason for tremendous excitement." Genentech Inc, the South San Francisco, Calif, genetic engineering firm that produces recombinant human tissue-type plasminogen activator in this country, he added, "has taken a [sparsely occurring native] molecule with great potential and produced it for practical
Goldsmith MF. Recombinant plasminogen agent continues to show promise in trials. JAMA. 1985;253(12):1693-1694. doi:10.1001/jama.1985.03350360017001